Piper Sandler Reiterates Overweight on Abbott Laboratories, Maintains $115 Price Target

Benzinga Newsdesk www.benzinga.com Negative 74.2%

Neg 74.2% Neu 0% Pos 0%

Piper Sandler analyst Adam Maeder reiterates Abbott Laboratories (NYSE:ABT) with a Overweight and maintains $115 price target.